BioNTech Acquires Rare Pediatric Disease Priority Review Voucher from Scholar Rock for $205 Million
BioNTech (BNTX) has entered into an agreement to acquire a Rare Pediatric Disease Priority Review Voucher (PRV) from Scholar Rock Holding (SRRK) for a total consideration of $205 million. The acquisition is part of BioNTech's strategic effort to accelerate the development and regulatory approval timelines for its oncology pipeline. The PRV provides the holder with an incentive by reducing the FDA’s review timeline for a future drug application. This transaction highlights the growing market value of priority review vouchers as biotechnology companies seek to expedite the commercialization of critical therapies.